<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18473">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099110</url>
  </required_header>
  <id_info>
    <org_study_id>8835-005</org_study_id>
    <nct_id>NCT02099110</nct_id>
  </id_info>
  <brief_title>Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin
      given together or alone along with metformin in participants with type 2 diabetes mellitus
      (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of
      this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater
      hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include a 1-week screening period; an up to 12-week metformin titration/dose
      stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase
      A and (26-week Phase B) double-blind treatment period and a post-treatment telephone contact
      14 days after the last dose of study medication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in A1C</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event (AE)</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Medication due to an AE</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Hemoglobin A1C of &lt;7%</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Parameters of Beta-cell Function</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin, oral, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg, oral, once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to Ertugliflozin 5 mg</intervention_name>
    <description>Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to Ertugliflozin 10 mg</intervention_name>
    <description>Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo to sitagliptin 100 mg</intervention_name>
    <description>Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg</intervention_name>
    <description>Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>JANUVIAÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin &gt;= 1500 mg/day</intervention_name>
    <description>Metformin &gt;= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Glargine Rescue Medication</intervention_name>
    <description>Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride Rescue Medication</intervention_name>
    <description>Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion</description>
    <arm_group_label>Ertugliflozin 5 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg + sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>AMARYL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus as per American Diabetes Association guidelines

          -  On metformin monotherapy (&gt;=1500 mg/day) for &gt;=8 weeks with a Visit 1/Screening A1C
             &gt;=7.5% and &lt;=11.0% (&gt;=58 mmol/mol and &lt;=97 mmol/mol) OR On metformin monotherapy
             (&gt;=1500 mg/day) for &lt;8 weeks with a Visit 1/Screening A1C &gt;=7.5% and &lt;=11.0% (&gt;=58
             mmol/mol and &lt;=97 mmol/mol) OR On metformin monotherapy &lt;1500 mg/day with a Visit
             1/Screening A1C &gt;=8.0% and &lt;=11.5% (&gt;=64 mmol/mol and &lt;=102 mmol/mol)

          -  Body mass index (BMI) &gt;=18.0 kg/m^2

          -  Male or female not of reproductive potential

          -  Female of reproductive potential who agrees to remain abstinent from heterosexual
             activity or to use 2 acceptable combinations of contraception

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or ketoacidosis

          -  History of other specific types of diabetes (e.g., genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
             post-organ transplant

          -  A known hypersensitivity or intolerance to any sodium glucose co-transporter (SGLT2)
             inhibitor or sitagliptin

          -  Has been treated with any of the following agents within 12 weeks of study start or
             during the pre-randomization period: Insulin of any type (except for short-term use
             [i.e., &lt;=7 days] during concomitant illness or other stress), other injectable
             anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone
             or rosiglitazone, other sodium glucose co-transporter 2 (SGLT2) inhibitors, alpha
             glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4
             inhibitor), sulfonylureas (SUs), bromocriptine (Cyclosetâ¢), colesevelam (Welcholâ¢),
             any other AHA with the exception of the protocol-approved agents

          -  Is on a weight-loss program or weight-loss medication or other medication associated
             with weight changes and is not weight stable prior to study start

          -  Has undergone bariatric surgery within the past 12 months or &gt;12 months and is not
             weight stable prior to study start

          -  A history of myocardial infarction, unstable angina, arterial revascularization,
             stroke, transient ischemic attack, or New York Heart Association (NYHA) functional
             class III-IV heart failure within 3 months of study start

          -  Active, obstructive uropathy or indwelling urinary catheter

          -  History of malignancy &lt;=5 years prior to study start, except for adequately treated
             basal cell or squamous cell skin cancer or in situ cervical cancer

          -  A known history of human immunodeficiency virus (HIV)

          -  A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a
             clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative
             or myelodysplastic syndromes, thrombocytopenia)

          -  A medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or
             symptomatic gallbladder disease

          -  Any clinically significant malabsorption condition

          -  Current treatment for hyperthyroidism

          -  On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior
             study start

          -  On a previous clinical study with ertugliflozin

          -  eGFR (using the 4-variable Modification of Diet in Renal Disease Study Equation
             (MDRD) equation) &lt;60 mL/min/1.73 m^2

          -  Serum creatinine &gt;= 1.3 mg/dL (115 Âµmol/L) for males and &gt;= 1.2 mg/dL (106 Âµmol/L)
             for females

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2 times upper
             limit of normal

          -  Hemoglobin &lt;12 g/dL (120 g/L) for males and &lt;11 g/dL (110 g/L) for females.

          -  Participated in other studies involving investigational drug(s) 30 days prior to
             study start

          -  Surgical procedure within 6 weeks prior to study start or major surgery planned
             during the trial

          -  Positive urine pregnancy test

          -  Pregnant or breast-feeding, or planning to conceive during the trial, including 14
             days following the last dose of study medication

          -  Planning to undergo hormonal therapy in preparation for egg donation during the
             trial, including 14 days following the last dose of study medication

          -  Routinely consumes &gt;2 alcoholic drinks per day or &gt;14 alcoholic drinks per week or
             engages in binge drinking

          -  Donated blood or blood products within 6 weeks of study start
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0078)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
